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ABSTRACT  
The intake of 3,4-methylenedioxymethamphetamine (MDMA) is known to increase several 
endogenous substances involved in steroid and inflammation pathways. Untargeted 
metabolomics screening approaches can determine biochemical changes after drug exposure 
and can reveal new pathways which might be involved in the pharmacology and toxicology of 
a drug of abuse. We analyzed plasma samples from a placebo-controlled cross-over study of a 
single intake of MDMA. Plasma samples from a time point before and three time points after 
the intake of a single dose of 125 mg MDMA were screened for changes of endogenous 
metabolites. An untargeted metabolomics approach on a high resolution quadrupole time of 
flight mass spectrometer coupled to liquid chromatography with two different chromatographic 
systems (reversed phase and hydrophobic interaction liquid chromatography) was applied. Over 
10’000 features of the human metabolome were discovered. Hence, 28 metabolites were 
identified which showed significant changes after administration of MDMA compared to 
placebo. The analysis revealed an upregulation of cortisol and pregnenolone sulfate four hours 
after MDMA intake suggesting increased stress and serotonergic activity. Further, calcitriol 
levels were decreased after the intake of MDMA. Calcitriol is involved in the upregulation of 
trophic factors which have protective effects on brain dopamine neurons. The inflammation 
mediators hydroxyeicosatetraenoic acid (HETE), dihydroxyeicosatetraenoic acid (diHETE) 
and octadecadienoic acid (oxoODE) were found to be upregulated after the intake of MDMA 
compared to placebo which suggested a stimulation of inflammation pathways.  
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INTRODUCTION 
3,4-Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) is a popular recreational drug. It 
acts as indirect monoaminergic agonist releasing serotonin (5-hydroxytryptamine; 5-HT), 
norepinephrine (NE) and dopamine (DA) by interacting with the respective membrane 
transporters [Hysek, 2012 #1243]. Little is known about peripheral and systemic changes on 
the level of endogenous metabolites caused by MDMA. MDMA increases 
glucocorticoids[Seibert, 2014 #3228], prolactin , oxytocin, and arginine vasopressin in line with 
its predominant action to increase 5-HT [Seibert, 2014 #3228;Hysek, 2012 #1243;Hysek, 2014 
#2475;Kirkpatrick, 2014 #5009;Simmler, 2011 #1172]. However, metabolic changes on a 
wider spectrum are unstudied. Additionally, MDMA can cause hyperthermia, cardiac, hepatic 
and immune changes 11,12[Pacifici, 2004 #288;Bigler, 2015 #4488]. Only a few studies have 
illustrated the effect of MDMA consumption on inflammation pathways. It activates microglia 
cells in the brain triggering the secretion of proinflammatory cytokines, nitric oxide, 
prostaglandins and other reactive species which promote neuroinflammation processes and can 
damage neuronal tissue 13,14.  
Metabolomics screening approaches are suitable tools for the high-throughput identification 
of many metabolites within one single sample. At best, it can reveal several pathways which 
may play an important role in drug consumption. In a first attempt looking only at a limited 
number of endogenous metabolites, we could show that a single intake of MDMA showed 
changes in certain amino acids (AA) and biogenic amines that are rather time-dependent than 
influenced by MDMA. The metabolic ratio methionine-sulfoxide over methionine (Met-
SO/Met) was increased after the intake of MDMA indicating an increase of systemic oxidative 
stress. Further, an increase of diacyl-phosphatidyl-cholines and acyl-alkyl phosphatidylcholines 
after the intake of MDMA was observed which can be interpreted as an upregulation in energy 
production and changes in cell functions and inflammation processes 15. Nielsen et al. 
retrospectively investigated forensic whole blood samples of humans exposed to MDMA with 
an untargeted screening approach and found among other metabolites changes of several 
acylcarnitines, lysophospatidylcholines (lysoPC), adenosine and inosine in response to MDMA 
16
.  
The human metabolome responds quite sensitive on many different influences such as food 
intake, stress, xenobiotics and physical exercise 17,18. In this follow-up study, we aimed to find 
a broader spectrum of endogenous pathways and metabolites which could be involved or 
affected after MDMA consumption. Therefore, the aim of this study was to extensively 
investigate changes of plasma metabolites in response to a single dose of 125 mg of MDMA. 
Samples from a placebo-controlled, double-blind crossover study [Schmid, 2015 #3774] were 
analyzed with an untargeted metabolomics screening method to cover as many endogenous 
metabolites as possible. 
 
 
METHODS AND MATERIALS 
Clinical Study 
Sample collection and details of the study have been published previously 15,19. The samples 
were stored at our institute (-80 °C). In brief, eight male and eight female subjects (age 20-27) 
were recruited. Drug use history of subjects and study inclusion criteria has been described in 
detail elsewhere 19,20. For the present analysis, only plasma samples from the session days where 
the participants took placebo or MDMA alone were used while other treatments were also 
administered in the study but not analyzed here. Wash-out periods between session days were 
at least 10 days. On the session days, MDMA (125 mg p.o., corresponding to 1.8 ± 0.2 mg/kg 
body weight) or placebo was ingested at 10 a.m. Plasma samples used for this study were 
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collected at 8 a.m. (= time point 0), 2 p.m. (=  time point 1), 6 p.m.(= time point 2), and the next 
day at 8 a.m. (= time point 3). A standardized meal was served at 12:30 p.m. during the session 
days. The clinical study was conducted at the University Hospital of Basel. The study was 
approved by the Ethics Committee of the Canton Basel, Switzerland and the Swiss Agency for 
Therapeutic Products (Swissmedics) and it was registered at ClinicalTrials.gov 
(NCT01771874). All subjects provided written informed consent and were paid for their 
participation.  
 
Chemicals and Reagents 
1-Methylhistidine, adenine, adenosine, arginine (arg), azelaic acid, chenodeoxycholic acid, 
cholic acid, citrulline, cortisol, cortisone, creatinine, deoxycholic acid, glutaric acid, 
glycocholic acid, hippuric acid, inosine, isoleucine (ile), leucine (leu), L-pyroglutamic acid, 
methionine (met), methylmalonic acid, mevalonolactone, N,N-dimethylglycine, nicotinic acid, 
p-aminobenzoic acid, phenylalanine (phe), proline (pro), raffinose, riboflavin, taurine, 
taurocholic acid, tryptophan, and uracil were purchased from Sigma-Aldrich (Buchs, 
Switzerland). Deuterated and heavy-labeled internal standards (IS) adenosine ribose-D1, 
arginine-13C6, caffeine 3-methyl-13C, carnitine trimethyl-D9, creatinine N-methyl-D3, 
deoxycholic acid-D4, D-fructose 13C, glycine-13C2, glycocholic acid-D4, hippuric acid 15N, 
kynurenine-D4, leucine-D10, lysine-D4, phenylalanine-D1, proline 15N, serine-D3, 
tryptophan-D5 and uric acid-15N2 were purchased from Cambridge isotope laboratories which 
were delivered by ReseaChem Life Science (Burgdorf, Switzerland) or Sigma-Aldrich (Buchs, 
Switzerland). Water, acetonitrile (ACN), methanol (MeOH) of HPLC grade were obtained from 
Fluka (Buchs, Switzerland). All other chemicals used were from Merck (Zug, Switzerland) and 
of the highest grade available. 
 
Sample preparation 
150 µl of plasma and 30 µl of the IS mixture (table S-1,supporting information) were added 
to a tube. Protein precipitation was performed by addition of 450 µl cooled MeOH/acetone 
(90:10 v/v). The mixture was vortexed, centrifuged (10 min, 14’000 x g) and 250 µl of the 
supernatant was transferred into two filter vials (0.45 µm PTFE, Thomson Instrument company, 
California, USA). Samples were stored at -20 °C until measurements on the UHPLC-Q TOF as 
described below. Additionally, pooled samples with 10 µl from every sample were prepared in 
the same manner and supernatant was aliquoted into six filter vials. 
 
UHPLC-Q TOF MS 
In total 128 samples (16 participants, 2 sessions, 4 time points) were subjected to mass 
spectrometric measurements. Samples were divided in two batches and a randomized analysis 
was performed on a Thermo Fischer Ultimate 3000 UHPLC system (Thermo Fischer Scientific, 
San Jose, CA) coupled to a high-resolution TOF instrument system (TripleTOF 6600, Sciex, 
Concord, Ontario, Canada). Mobile phases A and B consisted of 10 mM ammonium formate 
with 0.1 % (v/v) formic acid in water and 0.1 % (v/v) formic acid in MeOH, respectively. 
Mobile phases C and D were 25 mM ammonium acetate and 0.1 % (v/v) acetic acid in water 
and 0.1 % (v/v) acetic acid in ACN, respectively.  
Two different columns were used for chromatographic separation. A Waters (Baden-
Daettwil, Switzerland) XSelect HSST RP-C18 column (150 mm x 2.1 mm, 2.5 µm particle 
size) was applied with the following gradient: 1 min 100 % A; 1-15 min 100 % B; 15-18 min 
100 % and then decreased to start conditions and re-equilibration for 2 min. Flow rate increased 
after 15 min to 0.7 ml/min. Further a Merck SeQuant ZIC HILIC column (150 mm x 2.1 mm, 
3.5 µm particle size) using the following gradient: 1 min 95 % D; 1-10 min decrease to 40 % 
D; 10-12 min 10 decrease to 10 % D; 12-13 min 10 % D; and then increase to start conditions 
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and re-equilibration for 2 min was used. The column oven was set to 40 °C and injection volume 
was 1 µl for all samples. 
High resolution mass spectra (MS) and MS/MS data were acquired by the two methods: TOF 
MS only and information dependent data acquisition (IDA) in positive and negative ionization 
mode. MS analysis was performed with a DuoSpray ion source at a resolving power (full width 
at half-maximum at m/z 400) of 30’000 in MS and 30’000 in MS2 (high-resolution mode) or 
15’000 (high-sensitivity mode) in positive ionization mode. Automatic calibration was obtained 
every three sample injections using atmospheric-pressure chemical ionization (APCI) positive 
calibration solution (Sciex) in the positive ionization mode and every five sample injections 
using APCI negative calibration solution (Sciex) in the negative ionization mode. The TOF MS 
method was composed of a TOF-MS scan over a mass range from m/z 50 to m/z 1000 
(accumulation time 100 msec, CE 5 eV). Additionally, 20 % of the samples were measured in 
the IDA scan mode. The IDA method consisted of a TOF-MS scan over a mass range from m/z 
50 to m/z 1000 (accumulation time 50 msec, CE 5 eV). IDA experiments (accumulation time 
for each IDA experiment 100 msec, CE 35 eV with a CE spread of 15 eV) were performed after 
dynamic background subtraction on the four most intense ions with an intensity threshold above 
100 cps and exclusion time of 5 s (half peak width) after two occurrences in high sensitivity 
mode.  
A system suitability test (SST) containing 1-methylhistidine, adenine, adenosine, arg, azelaic 
acid, chenodeoxycholic acid, cholic acid, citrulline, cortisol, cortisone, creatinine, deoxycholic 
acid, glutaric acid, glycocholic acid, hippuric acid, inosine, ile, leu, L-pyroglutamic acid, met, 
methylmalonic acid, mevalonolactone, N,N-dimethylglycine, nicotinic acid, p-aminobenzoic 
acid, phe, pro, raffinose, riboflavin, taurine, taurocholic acid, tryptophan and uracil 
(concentration 10 µg/ml each) was measured after every fifth sample. The SST was checked 
for reproducibility of the data by retention time (RT) shifts and peak area comparison using 
MultiQuant V 2.1 (Sciex). Further, a pooled sample was additionally measured after every fifth 
sample. 
 
Data analysis and evaluation 
Progenesis QI (Waters Corp, Milford, USA) was used for data-preprocessing, alignment, 
deconvolution, peak-picking, identification and simple statistical calculations. Automatic 
processes were checked manually and pooled plasma samples were used as reference samples 
for data alignment. Data files of the IDA scan mode were incorporated in the software for 
identification purposes only to have MS/MS spectra of the most abundant compounds. 
Identification was performed by searching against an in-house library in PeakView V 2.2 
(Sciex) and against different online databases including METLIN 21, the Human Metabolome 
Database 22 (HMDB, V4.0), NIST 23 and Lipidblast 24 using Progenesis QI. The in-house 
database was further converted into MSP files and incorporated in Progenesis QI. 
Final identification results were classified on the different levels of identification confidence 
suggested by the metabolomics standard initiative (MSI) 25: Level 1, highest confidence based 
on matching exact mass, RT and fragmentation pattern with an in-house spectral library of 
standards collected under the same conditions. Level 2 requires spectrum and mass similarities 
to data available in public databases with reasonable RT. Level 3 assigns chemical classes based 
on spectral data and exact mass information relating on available public databases without 
retention time. Level 4 are unknown compounds. 
 
Statistical evaluation 
Statistical calculations were done with Prism 7 (GraphPad Software, CA, USA) and 
MetaboAnalyst 4.0 26. Normalization was conducted in Progenesis QI. Progenesis calculates a 
factor which will be multiplied by all compound ion abundances for each sample, to allow 
recalibration to a normalization reference run. A quantitative abundance ratio of all detected 
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ions was calculated between the normalized run and the pooled sample that was selected as 
reference sample.  
Prior to statistical calculations, a missing value imputation was conducted with the MetImp 
online tool 27. Random forest (RF) was chosen as imputation method for missing values 27,28. 
Two-way repeated measure analysis of variance (ANOVA) (within subject) was calculated for 
time series analysis with application of Tukey test for multiple comparison. Paired t-tests were 
calculated separately on every time point to identify statistically significant (p ≤ 0.01) 
differences between the two sessions. 
Partial least square discriminant analysis (PLS-DA) was applied on autoscaled data of 
important metabolites including MDMA and MDMA-metabolites from timepoint 1. Cross 
model validation and permutating testing for validation of the PLS-DA model was used.  
Baseline correction according to the first study was conducted for analytes, which showed a 
significant change (paired t-test, p ≤ 0.05) between time point 0 in the MDMA and placebo 
session 15. The peak area of the analyte measured at time point 0 was subtracted from the peak 
area of the analyte at the other time points to overcome interday variabilities. 
 
RESULTS AND DISCUSSION 
Instrument performance 
Analytes in the SST samples were normalized over the summarized intensities of all analytes 
to statistically equilibrate the instrument performance. Peak areas were calculated using 
Multiquant V2.1 (Sciex). The applied screening method has been extensively examined 
recently on analyte selection, detectability and sensitivity (unpublished work, Zurich Institute 
of Forensic Medicine, Switzerland, M.I. Boxler, T.D. Schneider, T. Kraemer, A.E. Steuer, May 
2018). Measurements on the HSST column showed constant peak areas of the analytes and 
were highly reproducible. Chenodeoxycholic acid and deoxycholic acid showed a decreasing 
trend which can be explained by substance instabilities. Uric acid showed unexpected 
fluctuations in all experiments due to non-constant chromatographic retention time of this 
substance. Analytes in the SST samples which were measured on the HILIC column showed a 
slight retention time shift and overall, the pressure during the runs was not as stable as for the 
measurements on the HSST column. Overall, all experiments were reproducible in terms of 
peak intensity and retention time continuity and were therefore used for the analysis of the data.  
 
Normalization  
Normalization techniques have to deal with technical variation which can bias the scaling 
factor. Normalization process of Progenesis QI was compared to normalization processes via 
total ion count (TIC). Both reduced the coefficient of variation (CV) well (data not shown) and 
CV’s were within the same range. However, to reduce overall calculations, the normalization 
process from Progenesis QI was finally selected and applied. Normalization processes via best-
match IS did lead to inferior results compared to the other two methods and was excluded as 
normalization method. Additionally, two samples from different time points were missing and 
missing value imputation was conducted. 
 
Baseline correction 
The multilevel structure of the dataset is quite complex and a good statistical strategy is 
necessary. In the first project, baseline correction was conducted on all metabolites and analytes 
were selected as statistically significant if the p-value was ≤ 0.01 15. With the baseline correction 
one can overcome interday variabilities, however it also removes drug-dependent changes in 
certain metabolites which are only little but could still be influenced by the intake of MDMA. 
For this extensive appraisal, baseline correction was only applied on certain metabolites. Peak 
areas of the identified metabolites were compared between the MDMA and placebo session at 
time point 0 and if there was a significant change (p ≤ 0.05, paired t-test) between the two 
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samples, a baseline correction was conducted. If there was no significant difference visible in 
the two samples, metabolites were compared without a baseline correction (table 1).  
 
Detection of MDMA and its metabolites 
An unambiguous identification of MDMA and its main metabolites could be achieved using 
accurate masses and retention times. The highly significant p-values, fold changes, congruent 
fragments in the MS/MS fragmentation spectra and the compound absence in the placebo 
conditions further verified the findings. MDMA itself was identified only in the positive mode 
of both column settings. Since MDMA and its metabolites carry a basic nitrogen group, 
negative ionization is unlikely. Furthermore 3,4-methylenedioxyampehtamine (MDA), 3,4-
dihydroxymethamphetamine sulfates (DHMA 3-sulfate and DHMA 4-sulfate respectively), 4-
hydroxy-3-methoxymethamphetamine sulfate (HMMA sulfate), HMMA glucuronide and an 
in-source fragment of MDMA could be identified either with HSST or HILIC in both ionization 
modes. A PLS-DA analysis was conducted with MDMA, MDMA-metabolites and metabolites 
which were identified and statistically significant between the two sessions. A separation of the 
MDMA and the placebo group could be achieved (first component R2 = 0.83, Q2 = 0.78), with 
MDMA and its metabolites showing the highest variable importance parameters (VIPs) scores 
and therefore were primarily responsible for the group separation. The PLS-DA plot was 
validated and the p-value (p < 0.001) of the prediction errors from 1000 randomly permutated 
data sets revealed a valid model with no overfit (figure 1). The separation of the two groups 
with MDMA and its metabolites having the highest impact was predictable and showed, that 
the applied screening method operated well. 
 
Identified endogenous metabolites 
With all four chromatographic modes (HSST positive and negative, HILIC positive and 
negative) around 36’000 compound ions were found, with the majority of the compound ions 
found in the positive ionization mode. After data processing with the data from the IDA mode, 
10’400 features were detected with an MS/MS spectrum. These features were further processed 
and statistically evaluated with fold change analysis. Time points were viewed separately and 
features with a fold change 2 or higher were selected for metabolite identification.  
A total of 28 metabolites with an identification level of 2 or higher were detected, which 
showed a significant change (p ≤ 0.01) between the MDMA and placebo session and/or the 
different time points (table 1). These metabolites do not include MDMA and MDMA 
metabolites. Further 27 metabolites and features respectively with an identification level of 3 
or 4, fold change analysis > 2 and significant changes (p ≤ 0.05, repeated measured ANOVA) 
between the MDMA and placebo session were detected with Progenesis Qi (table S-2, 
supporting information). Different lipids were identified, a diacylglycerid (DG(x:y)), 
lysophosphatidylcholines (lysoPCx:y), lysophosphatidylethanolamines (lysoPEx:y/x:y), 
glycerophosphatidylcholines (GPChox:y/x:y) and glycerophosphatidylethanolamine 
(GPEtnx:y/x:y). The side chains are indicated with “x:y” where ‘x’ describes the number of 
carbons and ‘y’ the number of double bonds. The identified metabolites are listed in table 1. In 
the discussion, we mainly focused on alterations of steroid and inflammation pathways. 
 
Effects of MDMA intake 
In the previous publication, we stated that certain AA such as alanine, or tryptophan as well 
as other metabolites like taurine, creatinine and kynurenine underwent time-dependent changes 
independent from the MDMA intake. The metabolic ratio Met-SO/Met was increased after the 
intake of MDMA due to formation of reactive oxygen species after MDMA consumption. 
Further, an increase of fatty acids after the intake of MDMA was explained with a higher energy 
demand and production due to increased activity and cardiac stress 15. Here in the second study, 
we only statistically analyzed features respectively metabolites, which showed a fold change 
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greater than two between the placebo and the MDMA session. This statistical test omitted 
metabolites that showed only time-dependent changes. With this untargeted screening method, 
tryptophan showed statistically significant changes between the time points, but since we did 
not apply baseline correction on every metabolite, tryptophan showed also a statistically 
significant downregulation after MDMA intake compared to placebo at time point 1 (paired t-
test, p = 0.01) which is congruent to the findings of Nielsen et al. 16. Tryptophan is an important 
AA for the synthesis of 5-HT which is suggested to be upregulated after MDMA consumption 
11,29
.  
 
Steroid metabolism 
Focusing on the steroid metabolism, three altered metabolites could be identified and 
characterized. Cortisol was unambiguously identified and showed highly significant changes at 
time point 1 (p = 0.0003). Compared to the intake of placebo, cortisol levels increased after the 
intake of MDMA before lowering back down on the same level as after placebo consumption 
(figure 2). These findings were already described in targeted studies on cortisol changes based 
on MDMA intake 30-32. Cortisol is a glucocorticoid steroid which is released in response to 
stress or low blood-glucose concentration and it is also a marker for serotonergic activity 33. 
MDMA is further known to increase the secretion of prolactin, another serotonergic activity 
marker, and noradrenaline (NA), which plasma levels represent mostly an overflow of NA from 
the sympathetic nerves 30. 
Moreover, pregnenolone sulfate (PregS) was elevated at time point 1 and 2 (p = 0.0003 and 
p = 0.043 respectively). It is a neuroactive steroid that is synthesized from pregnelonone (Preg) 
34
. Cholesterol is converted into Preg which is the first step in the steroid-synthesis. Preg can 
further undergo various metabolic pathways and is mainly converted to PregS, progesterone 
(Prog) and 17-hydroxypregnenolone in humans 35. Harris et al. investigated effects of a single 
intake of MDMA on various hormones including progesterone in the female participants (n = 
3). They reported a progesterone increase after the intake of MDMA but the changes were not 
statistically significant compared to a placebo intake 36. Progesterone can be metabolized to 17-
hydroxyprogesterone which is further metabolized to glucocorticoids, mainly cortisol, or to 
androstenediones. In our study, the active steroid PregS showed a similar abundance profile as 
cortisol which supports the connected behavior. PregS regulates many brain functions by 
binding to γ-aminobutyric acid (GABAA) and N-methyl-D-aspartate (NMDA) type receptors 
with high affinity 35. Le Mélledo et. al. showed, that plasma PregS levels were significantly 
reduced in male patients with generalized anxiety disorders or with generalized social phobia 
compared to healthy male subjects 37,38.  
Calcitriol, the active metabolite of vitamin D3, showed a highly significant decrease at time 
point 1 (p = 0.0002) after the intake of MDMA compared to the placebo intake (figure 2). This 
metabolite has potent effects on brain cells and may appear to upregulate trophic factors 
including the glial cell line-derived neurotrophic factor (GDNF) which has protective effect on 
brain DA neurons 39. Cass et al. showed, that a treatment with calcitriol can protect against 
dopamine and serotonin depleting effects of neurotoxic doses of methamphetamine in rats. 
Animals which were treated with calcitriol showed significantly less methamphetamine 
reductions in DA, 5-HT and metabolites compared to the animals which were treated with 
placebo 40. Methamphetamine and MDMA share structure similarities with similar neurotoxic 
effects 2. Although these discussed metabolites can cross the blood brain barrier, the relevance 
of plasma levels to central nervous system activity is difficult to determine 40,41. A complete 
and targeted analysis focusing on these pathways only would possibly reveal further 
connections. 
 
Inflammation pathways 
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As already discussed in the first publication, reactive quinone-metabolites of MDMA can 
produce semiquinone radicals causing the generation of reactive oxygen species (ROS) which 
can lead to systemic oxidative stress and inflammation processes 42,43. The three putatively 
identified metabolites, a hydroxyl-eicosatetraenoic acid (HETE) derivative, dihydroxy-
eicosatetraenoic acid (diHETE) and an oxo-octadecanedienoic acid (oxoODE) are 
inflammation mediators. The positions of the functional groups were not completely 
determinable based on the acquired measurements. With referral to the fragmentation data the 
compounds might be 5-HETE, 5,12-diHETE, and 13-oxoODE. These three metabolites showed 
similar trends over the analyzed time points with significantly increased peak areas after the 
intake of MDMA compared to placebo (figure 3). 12-diHETE was baseline corrected. Anneken 
et al described that there are multiple signaling pathways through which MDMA may increase 
cyclooxygenase (COX) activity and the subsequent production of prostaglandins 44. 
Polyunsaturated fatty acids such as linoleic acid (LA) and arachidonic acid are oxidized to fatty 
acid hydroperoxides. In a first step, LA is oxidized to the peroxide 
hydroperoxyoctadecanedinoic acid (HPODE) which is then reduced to 9- and 13-HODE and 
further dehydrogenated to oxoODE. Similarly, arachidonic acid is oxidized to 
hydroperoxyeicosatetraenoic acid (HPETE) and reduced to HETE. A product of HETE is 
diHETE via an oxidation and reduction step. These arachidonic acid products which are isomers 
of leukotriene B4, were discussed as pro-inflammatory agents 45,46. 13-oxoODE has also anti-
inflammatory effects 47. For a broad analysis of these inflammation mediators in dependence of 
a MDMA intake, more metabolites from these involved pathways need to be investigated but 
these findings may serve as first valuable indicators.  
Neurotransmitters such as DA and 5-HT, which play an important role in the pharmacology 
of MDMA, were not analyzed with the screening method. A targeted search for these 
metabolites was not conducted since plasma levels of these neurotransmitters can’t be 
correlated to levels in the brain without special sample preparation and handling of the plasma 
48
. 
 
CONCLUSION 
The metabolites involved in steroid and inflammation pathways which could be identified 
showed statistically significant changes after a single intake of MDMA compared to placebo, 
indicating increased stress, serotonergic activity and inflammation processed in the human 
body. With these results, we were able to confirm findings from a previous study on only a 
limited number of metabolites and were able to show additional markers mainly from steroid- 
or inflammation pathways. . Untargeted metabolomics screening methods are a useful tool to 
get an insight in pathways which might be involved in the pharmacology and toxicology of a 
drug of abuse such as MDMA. However, as these pathways are quite complex and many 
endogenous metabolites are involved, further selective analysis of the individual pathways 
which showed to be altered after consumption would be necessary to obtain deeper insights into 
the underlying mechanisms.   
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FIGURES  
 
Figure 1. PLS-DA scores plot at timepoint 1. MDMA (green) or placebo (red) intake of 16 
participants and resulting 95% confidence region. Further VIP scores of component 1 of top 15 
metabolites are listed. 
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Figure 2. Metabolites of the steroid family which showed significant differences between 
MDMA and placebo intake. Squares represent the MDMA session and triangles represent the 
placebo session. Mean values with standard error measurements (SEM). Significance level is 
indicated with asterisks (* = 0.05-0.01; ** = 0.01-0.001; *** = 0.001-0.0001)   
  
 11
 
 
Figure 3. Inflammation mediators, squares represent the MDMA session and triangles the 
placebo session. Mean values with standard error measurements (SEM). Significance level is 
indicated with asterisks (* = 0.05-0.01; ** = 0.01-0.001; *** = 0.001-0.0001)   
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TABLES.  
Table 1. Identified metabolites which showed a significant change between the MDMA and placebo session, arranged in compound 
classes 
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tp 0 Time-points sessions 
Inter-
action tp 1 tp 2 tp 3 
Spinganine Amine 302.304 [M+H]+ 2 HSST pos. n.s. n.s. ** * 0.0001 n.s. n.s. 
Arginine Amino acid 175.1189 [M+H]+ 1 HSST pos. n.s. n.s. ** n.s. 0.0002 n.s. n.s. 
Glutamine Amino acid 147.0758 [M+H]+ 1 HSST pos. n.s. n.s. * n.s. 0.0052 n.s. n.s. 
Histidine Amino acid 156.0764 [M+H]+ 1 HSST pos. n.s. n.s. * n.s. 0.0012 n.s. n.s. 
Methionine Amino acid 150.0567 [M+H]+ 1 HILIC pos. n.s. n.s. **** n.s. 0.0014 0.0046 n.s. 
Trimethylglycine Amino acid 118.0859 [M+H]+ 2 HSST pos. n.s. *** * ** 0.0014 n.s. n.s. 
Tryptophan Amino acid 205.0967 [M+H]+ 1 HSST pos. n.s. ** * n.s. 0.0098 n.s. n.s. 
Tyrosine Amino acid 180.0666 [M-H]- 1 HILIC neg. n.s. * *** * 0.0001 0.002 n.s. 
Biliverdin Bilirubin 583.2543 [M+H]+ 2 HILIC pos. n.s. * ** * 0.0022 n.s. n.s. 
Carnitine Carnitine 162.1123 [M+H]+ 1 HSST pos. n.s. n.s. * n.s. 0.0016 n.s. n.s. 
  
 
184.092 [M+Na]+ 
         
Propionylcarnitine Carnitine 218.1381 [M+H]+ 1 HSST pos. n.s. ** ** n.s. 0.0043 n.s. n.s. 
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Hydroxyeicosatetraenoic 
acid Eicosanoid 319.2288 [M-H]
-
 2 HILIC neg. n.s. n.s. ** n.s. 0.0097 n.s. n.s. 
Oleamide Fatty acid 282.2795 [M+H]+ 2 HSST pos. n.s. n.s. * n.s. 0.0008 n.s. n.s. 
  
 
304.2602 [M+Na]+ 
         
Docosenamide Fatty amide 338.3414 [M+H]+ 2 HSST pos. n.s. n.s. * n.s. 0.0004 n.s. n.s. 
  
 
360.3234 [M+Na]+ 
         
Hexadecanoyl glycerol Glycerolipid 331.283 [M+H]+ 2 HSST pos. n.s. n.s. ** * n.s. n.s. 0.0022 
Glycerol stearate  Glycerolipid 359.3157 [M+H]+ 2 HSST pos. n.s. n.s. * n.s. n.s. n.s. 0.0035 
  
 
376.3423 [M+NH4]+
 
         
    381.2974 [M+Na]+ 
         
  
 
341.305 [M+H-H2O]+          
GPCho (16:0/18:2) 
Glycerophosphatid
yl-cholines 758.5691 [M+H]
+
 2 HSST pos. n.s. n.s. ** n.s. 0.0027 n.s. 0.001 
GPCho (18:2/18:2) 
(PC(36:4)) 
Glycerophosphatid
yl-cholines 782.5679 [M+H]
+
 2 HSST pos. n.s. n.s. *** n.s. n.s. n.s. <0.0001 
Dihydroxyeicosatetra-
enoic acid  Leukotriene 335.2233 [M+H]
+
 2 HILIC neg. BC *** *** n.s. <0.00001 <0.00001 0.0037 
Octadecadienoic acid Linoelic acid 293.2114 [M-H]- 2 HILIC neg. n.s. n.s. ** n.s. n.s. 0.0083 n.s. 
LysoPC (18:2) 
Lysophosphadityl-
choline 520.3402 [M+H]
+
 2 HSST pos. n.s. n.s. ** n.s. n.s. n.s. 0.0034 
LysoPC (18:3) 
Lysophosphadityl-
choline 518.321 [M+H]
+
 2 HILIC pos. n.s. n.s. *** n.s. <0.0001 n.s. n.s. 
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LysoPC (22:6) 
Lysophosphatidyl-
choline 568.3391 [M+H]
+
 2 HSST pos. n.s. n.s. ** n.s. 0.0065 n.s. 0.0091 
LysoPE (18:0/0:0) 
Lysophosphatidyl-
ethanolamine 480.3064 [M-H]
-
 1 HSST neg. BC n.s. ** * 0.0002 n.s. n.s. 
LysoPE (18:2/0:0) 
Lysophosphatidy-
lethanolamine 476.2791 [M-H]
-
 2 HILIC neg. n.s. * *** n.s. n.s. 0.0009 <0.0001 
Calcitriol Steroid 399.3252 
M+H-
H2O 2 HSST pos. n.s. n.s. n.s. n.s. 0.0002 n.s. n.s. 
Cortisol Steroid 363.2147 [M+H]+ 1 HSST pos. n.s. **** ** *** 0.0003 n.s. n.s. 
Pregnenolone sulfate Steroid 395.1877 [M-H]- 2 HSST neg. n.s. **** *** **** 0.0003 n.s. n.s. 
ametabolites were identified based on different levels of identification confidence suggested by the metabolomics standard initiative 
25
. 
bpaired t-tests at timepoint 0 were conducted to see if baseline correction (BC) is necessary. cSignificance level is indicated with 
asteriks (n.s. = not significant; * = 0.05-0.01; ** = 0.01-0.001; *** = 0.001-0.0001)   
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ABBREVIATIONS 
MDMA, 3,4-methylenedioxymethamphetamine; UHPLC-QTOF, high resolution quadrupole time 
of flight mass spectrometer coupled to liquid chromatography; HILIC, hydrophobic interaction 
liquid chromatography; HETE, hydroxyeicosatetraenoic acid; diHETE, dihydroxyeicosatetraenoic 
acid; oxoODE, octadecadienoic acid; DA, dopamine; 5-HT, 5-hydroxytryptamine; AA, amino 
acids; Met-SO/Met, methionine-sulfoxide over methionine; lysoPC, lysophospatidylcholines; 
Arg, arginine; ile, isoleucine; leu, leucine; met, methionine; phe, phenylalanine; pro, proline; IS, 
internal standard; CAN, acetonitrile; MeOH, methanol; MS, mass spectra; IDA, information 
dependent data acquisition; APCI, atmospheric-pressure chemical ionization; SST, system 
suitability test; MSI, metabolomics standard initiative; RF, random forest; ANOVA, analysis of 
variance; PLS-DA, partial least square discriminant analysis; TIC, total ion count; CV, coefficient 
of variation; MDA, 3,4-methylenedioxyampehtamine; DHMA, 3,4-dihydroxymethamphetamine; 
HMMA, 4-hydroxy-3-methoxymethamphetamine; VIP, variable importance parameters; DG, 
diacylglycerid; lysoPE, lysophosphatidylethanolamines; GPCho, glycerophosphatidylcholines; 
GPEtn, glycerophosphatidylethanolamine; NA, noradrenaline; PregS, pregnenolone sulfate; Preg, 
pregnenolone; Prog, progesterone; GABA, γ-aminobutyric acid; NMDA, N-methyl-D-aspartate; 
GDNF, glia cell line-derived neurotrophic factor; COX, cyclooxygenase; LA, linoleic acid; 
HPODE, hydroperoxyoctadecanedinoic acid; HODE, hydroperoxyoctadecanedinoic acid; 
HPETE, hydroperoxyeicosatetraenoic acid 
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